Junji Tsurutani Advanced Cancer Translational Research Institute Showa University Biography Publications Institution JoVE Articles Junji Tsurutani has not added a biography. If you are Junji Tsurutani and would like to personalize this page please email our Author Liaison for assistance. Publications [fam-] Trastuzumab Deruxtecan, Antitumor Activity is Dependent on HER2 Expression Level Rather Than on HER2 Amplification International Journal of Cancer. May, 2019 | Pubmed ID: 31087550 Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-positive Gastric Cancer: a Dose-expansion, Phase 1 Study The Lancet. Oncology. Jun, 2019 | Pubmed ID: 31047804 Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-positive Breast Cancer Previously Treated with Trastuzumab Emtansine: a Dose-expansion, Phase 1 Study The Lancet. Oncology. Jun, 2019 | Pubmed ID: 31047803 Targeting of the HER2/HER3 Signaling Axis Overcomes Ligand-mediated Resistance to Trastuzumab in HER2-positive Breast Cancer Cancer Medicine. Mar, 2019 | Pubmed ID: 30701699 Mutational Activation of the Epidermal Growth Factor Receptor Down-regulates Major Histocompatibility Complex Class I Expression Via the Extracellular Signal-regulated Kinase in Non-small Cell Lung Cancer Cancer Science. Jan, 2019 | Pubmed ID: 30390416 Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients Treated with Eribulin: Interim Data from a Post-marketing Observational Study Breast Cancer (Tokyo, Japan). Mar, 2019 | Pubmed ID: 30324551 and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in Molecular Cancer Therapeutics. 01, 2019 | Pubmed ID: 30322949 Safety and Effectiveness of Eribulin in Japanese Patients with Locally Advanced or Metastatic Breast Cancer: a Post-marketing Observational Study Investigational New Drugs. 12, 2017 | Pubmed ID: 28660549 Üç Afatinib dirençli akciğer adenokarsinoma PC-9 hücre hatları Afatinib artan dozlarda ile geliştirilen kurulması ve karakterizasyonu Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 Cancer Research
Üç Afatinib dirençli akciğer adenokarsinoma PC-9 hücre hatları Afatinib artan dozlarda ile geliştirilen kurulması ve karakterizasyonu Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 Cancer Research
